Product Data Sheet

LTB4 antagonist 1

Cat. No.: HY-149082 CAS No.: 2929239-84-7 Molecular Formula: $C_{26}H_{23}NO_{6}$

Molecular Weight: 445.46

Target: Leukotriene Receptor Pathway: GPCR/G Protein

Storage: Please store the product under the recommended conditions in the Certificate of

BIOLOGICAL ACTIVITY

Description LTB4 antagonist 1, a carboxamide-acid compound, is a potent Leukotriene B4 (LTB4) antagonist with an IC50 of 288 nM. LTB4 antagonist 1 has significant anti-inflammatory properties^[1].

IC₅₀ & Target LTB₄

In Vivo LTB4 antagonist 1 (compound 24b; 30 mg/kg; orally) has a significant anti-inflammatory activity after 1 h in the model of podal edema with carrageenan in rats^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	The model of podal edema with carrageenan in rats $^{[1]}$
Dosage:	30 mg/kg
Administration:	Orally; single dose
Result:	After 1 h, a significant anti-inflammatory activity was observed (percentage inhibition of the edema: 39.7%) on carrageenan compared to the control group. After 2 h, the anti-inflammatory activity decreases sharply (16.2%). This activity completely disappeared after 4 h under TUKEY test.

REFERENCES

[1]. Latifa Bouissane, et al. New and promising type of leukotriene B4 (LTB4) antagonists based on the 1,4-benzodioxine structure. Eur J Med Chem. 2023 Apr 6;254:115332.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA